34,066 views
The number of cancer drugs used in Germany is increasing year by year; in 2016, statutory health insurance spent 5.7 billion euros on them. But that does not automatically mean that those affected have a higher chance of survival. A new study by King's College London shows that for half of all cancer conditions, the drugs approved in the EU between 2009 and 2013 have no relevant additional benefit. Experts have been calling for different approval rules and stricter follow-up controls for years. But politicians - including in Germany - are turning a blind eye to this.